Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Clinical risk profile score predicts all cause mortality but not implantable cardioverter defibrillator intervention rate in a large unselected cohort of patients with congestive heart failure

Sjöblom, Johanna ; Borgquist, Rasmus LU orcid ; Gadler, Fredrik ; Kalm, Torbjörn ; Ljung, Lina ; Rosenqvist, Mårten ; Frykman, Viveka and Platonov, Pyotr G LU (2017) In Annals of Noninvasive Electrocardiology 22(3).
Abstract

BACKGROUND: Primary prophylactic implantable cardioverter defibrillator (ICD) therapy is indicated for patients with reduced left ventricular ejection fraction (LVEF). We aimed to determine if preoperative clinical risk profiling can predict long-term benefit, and if clinical risk scores can be applied and improved in a patient cohort outside the clinical trial setting.

METHODS: Using registry data, 789 patients with reduced LVEF who received ICDs for primary prevention during 2006-2011 were identified (age 64 ± 11 years, 82% men, 63% ischemic etiology, 52% cardiac resynchronization therapy with defibrillator). The patients were divided into three risk groups, based on the presence of baseline clinical risk factors (age >70,... (More)

BACKGROUND: Primary prophylactic implantable cardioverter defibrillator (ICD) therapy is indicated for patients with reduced left ventricular ejection fraction (LVEF). We aimed to determine if preoperative clinical risk profiling can predict long-term benefit, and if clinical risk scores can be applied and improved in a patient cohort outside the clinical trial setting.

METHODS: Using registry data, 789 patients with reduced LVEF who received ICDs for primary prevention during 2006-2011 were identified (age 64 ± 11 years, 82% men, 63% ischemic etiology, 52% cardiac resynchronization therapy with defibrillator). The patients were divided into three risk groups, based on the presence of baseline clinical risk factors (age >70, QRS duration >120 ms, New York Heart Association class III-IV, atrial fibrillation history, or creatinine >106 μmol/L). Endpoints were all-cause mortality and survival free of adequate ICD therapy.

RESULTS: Mean follow-up was 39 ± 18 months. Annual mortality was 7.6%, and increased with risk group (p < .001). Rates of appropriate antitachycardia pacing and shock therapy were not statistically different between the groups, and ranged from 11%-16% and 6%-14%, respectively. By combining the previous risk score with data on diabetes, a better independent prediction of mortality was achieved; mortality rates then ranged from 11% (low-risk) to 46% (high-risk) (p < .0001).

CONCLUSIONS: Implantable cardioverter defibrillator therapies occur across the spectrum of comorbidities in a population with systolic heart failure. However, all-cause mortality is considerably higher in the group of patients with accumulated risk factors, and using the proposed scoring system can be helpful for the evaluation and risk stratification of the patient prior to making a decision for a primary prophylactic ICD implantation.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Noninvasive Electrocardiology
volume
22
issue
3
article number
e12414
publisher
Wiley-Blackwell
external identifiers
  • scopus:84996564538
  • wos:000404596800005
  • pmid:27800644
ISSN
1082-720X
DOI
10.1111/anec.12414
language
English
LU publication?
yes
id
314746d7-e760-4204-86bf-4bd563fd5923
date added to LUP
2016-11-24 21:15:23
date last changed
2024-08-09 23:25:12
@article{314746d7-e760-4204-86bf-4bd563fd5923,
  abstract     = {{<p>BACKGROUND: Primary prophylactic implantable cardioverter defibrillator (ICD) therapy is indicated for patients with reduced left ventricular ejection fraction (LVEF). We aimed to determine if preoperative clinical risk profiling can predict long-term benefit, and if clinical risk scores can be applied and improved in a patient cohort outside the clinical trial setting.</p><p>METHODS: Using registry data, 789 patients with reduced LVEF who received ICDs for primary prevention during 2006-2011 were identified (age 64 ± 11 years, 82% men, 63% ischemic etiology, 52% cardiac resynchronization therapy with defibrillator). The patients were divided into three risk groups, based on the presence of baseline clinical risk factors (age &gt;70, QRS duration &gt;120 ms, New York Heart Association class III-IV, atrial fibrillation history, or creatinine &gt;106 μmol/L). Endpoints were all-cause mortality and survival free of adequate ICD therapy.</p><p>RESULTS: Mean follow-up was 39 ± 18 months. Annual mortality was 7.6%, and increased with risk group (p &lt; .001). Rates of appropriate antitachycardia pacing and shock therapy were not statistically different between the groups, and ranged from 11%-16% and 6%-14%, respectively. By combining the previous risk score with data on diabetes, a better independent prediction of mortality was achieved; mortality rates then ranged from 11% (low-risk) to 46% (high-risk) (p &lt; .0001).</p><p>CONCLUSIONS: Implantable cardioverter defibrillator therapies occur across the spectrum of comorbidities in a population with systolic heart failure. However, all-cause mortality is considerably higher in the group of patients with accumulated risk factors, and using the proposed scoring system can be helpful for the evaluation and risk stratification of the patient prior to making a decision for a primary prophylactic ICD implantation.</p>}},
  author       = {{Sjöblom, Johanna and Borgquist, Rasmus and Gadler, Fredrik and Kalm, Torbjörn and Ljung, Lina and Rosenqvist, Mårten and Frykman, Viveka and Platonov, Pyotr G}},
  issn         = {{1082-720X}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Annals of Noninvasive Electrocardiology}},
  title        = {{Clinical risk profile score predicts all cause mortality but not implantable cardioverter defibrillator intervention rate in a large unselected cohort of patients with congestive heart failure}},
  url          = {{http://dx.doi.org/10.1111/anec.12414}},
  doi          = {{10.1111/anec.12414}},
  volume       = {{22}},
  year         = {{2017}},
}